KYMR Stock Overview
A biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Kymera Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$49.98 |
52 Week High | US$51.26 |
52 Week Low | US$9.60 |
Beta | 2.22 |
11 Month Change | 4.60% |
3 Month Change | 60.45% |
1 Year Change | 227.74% |
33 Year Change | -21.40% |
5 Year Change | n/a |
Change since IPO | 50.27% |
Recent News & Updates
Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up
Jul 14Recent updates
Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up
Jul 14Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being
Jun 12We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth
May 03Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Kymera KT-333 gets FDA orphan drug status for blood cancer subtype
Sep 15Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces
Aug 15Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M
Aug 09Shareholder Returns
KYMR | US Biotechs | US Market | |
---|---|---|---|
7D | 3.1% | -1.3% | 1.2% |
1Y | 227.7% | 23.2% | 30.2% |
Return vs Industry: KYMR exceeded the US Biotechs industry which returned 23.2% over the past year.
Return vs Market: KYMR exceeded the US Market which returned 30.2% over the past year.
Price Volatility
KYMR volatility | |
---|---|
KYMR Average Weekly Movement | 10.6% |
Biotechs Industry Average Movement | 10.2% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KYMR's share price has been volatile over the past 3 months.
Volatility Over Time: KYMR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 181 | Nello Mainolfi | www.kymeratx.com |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus.
Kymera Therapeutics, Inc. Fundamentals Summary
KYMR fundamental statistics | |
---|---|
Market cap | US$3.17b |
Earnings (TTM) | -US$157.85m |
Revenue (TTM) | US$88.55m |
36.0x
P/S Ratio-20.2x
P/E RatioIs KYMR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
KYMR income statement (TTM) | |
---|---|
Revenue | US$88.55m |
Cost of Revenue | US$209.11m |
Gross Profit | -US$120.56m |
Other Expenses | US$37.30m |
Earnings | -US$157.85m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.48 |
Gross Margin | -136.15% |
Net Profit Margin | -178.27% |
Debt/Equity Ratio | 0% |
How did KYMR perform over the long term?
See historical performance and comparison